Regenxbio Q3 revenue falls on lower ZOLGENSMA royalties

By Reuters News


Overview

  • US gene therapy developer's Q3 revenue declined yr/yr, mainly due to lower ZOLGENSMA royalties

  • Q3 net loss narrowed compared to prior year quarter

  • Company recorded $38 mln gain from Sarepta litigation settlement


Outlook

  • Company expects current cash resources to fund operations into late Q4 2027

  • Company expects topline data from pivotal wet AMD trials in Q4 2026


Result Drivers

  • ROYALTY DECLINE - Co said revenue drop was mainly due to lower ZOLGENSMA royalties following U.S. patent expiration

  • HIGHER R&D SPENDING - Co said increased R&D costs were mainly due to RGX-202 clinical trial expenses


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 License & Royalty Revenue

$5.24 mln

Q3 Net Loss

$40.74 mln

Q3 Operating Expenses

$44.70 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for REGENXBIO Inc. is $20.00, about 159.4% above its November 4 closing price of $7.71


Reuters Recommended Reads

  • Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027

  • Nov 4 - Netherlands' uniQure Q3 revenue misses estimates

  • Nov 3 - Denali Therapeutics swings to Q3 net profit on one-time gain


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.